Drug Watch

January 28th 2025

Check out new positive topline results from the open-label phase 2A study of BPL-003 in participants with moderate-to-severe alcohol use disorder.

January 28th 2025

Neurocrine is initiating a phase 3 study of osavampator for the treatment of adults with major depressive disorder.

January 22nd 2025

Here's why you should be paying attention to this new, upcoming Alzheimer disease treatment...

January 21st 2025

The FDA has approved the supplemental New Drug Application for Spravato, the first and only monotherapy for adults with treatment-resistant depression.